These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

156 related articles for article (PubMed ID: 28503810)

  • 41. Antithrombin deficiency after prolonged asparaginase treatment in children with acute lymphoblastic leukemia.
    Ranta S; Heyman MM; Jahnukainen K; Taskinen M; Saarinen-Pihkala UM; Frisk T; Söderhäll S; Petrini P; Mäkipernaa AM
    Blood Coagul Fibrinolysis; 2013 Oct; 24(7):749-56. PubMed ID: 24056293
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Intravenous pegylated asparaginase versus intramuscular native Escherichia coli L-asparaginase in newly diagnosed childhood acute lymphoblastic leukaemia (DFCI 05-001): a randomised, open-label phase 3 trial.
    Place AE; Stevenson KE; Vrooman LM; Harris MH; Hunt SK; O'Brien JE; Supko JG; Asselin BL; Athale UH; Clavell LA; Cole PD; Kelly KM; Laverdiere C; Leclerc JM; Michon B; Schorin MA; Welch JJ; Lipshultz SE; Kutok JL; Blonquist TM; Neuberg DS; Sallan SE; Silverman LB
    Lancet Oncol; 2015 Dec; 16(16):1677-90. PubMed ID: 26549586
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Thrombosis in children with acute lymphoblastic leukemia treated at a tertiary care center in Lebanon: revisiting the role of predictive models.
    Al-Aridi C; Abboud MR; Saab R; Eid D; Jeha S; Chan AK; Muwakkit SA
    Pediatr Hematol Oncol; 2011 Nov; 28(8):676-81. PubMed ID: 21787123
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Outcome of pediatric patients with acute lymphoblastic leukemia/lymphoblastic lymphoma with hypersensitivity to pegaspargase treated with PEGylated Erwinia asparaginase, pegcrisantaspase: A report from the Children's Oncology Group.
    Rau RE; Dreyer Z; Choi MR; Liang W; Skowronski R; Allamneni KP; Devidas M; Raetz EA; Adamson PC; Blaney SM; Loh ML; Hunger SP
    Pediatr Blood Cancer; 2018 Mar; 65(3):. PubMed ID: 29090524
    [TBL] [Abstract][Full Text] [Related]  

  • 45.
    Mootoosamy C; Kondyli M; Serfaty SA; Tremblay DÉ; Gagné V; Ribère M; Laverdière C; Leclerc JM; Sinnett D; Tran TH; Krajinovic M
    Pharmacogenomics; 2023 Mar; 24(4):199-206. PubMed ID: 36946317
    [TBL] [Abstract][Full Text] [Related]  

  • 46. The impact of prophylactic fresh-frozen plasma and cryoprecipitate on the incidence of central nervous system thrombosis and hemorrhage in children with acute lymphoblastic leukemia receiving asparaginase.
    Abbott LS; Deevska M; Fernandez CV; Dix D; Price VE; Wang H; Parker L; Yhap M; Fitzgerald C; Barnard DR; Berman JN
    Blood; 2009 Dec; 114(25):5146-51. PubMed ID: 19822902
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Asparaginase Therapy in Pediatric Acute Lymphoblastic Leukemia: A Focus on the Mode of Drug Resistance.
    Chen SH
    Pediatr Neonatol; 2015 Oct; 56(5):287-93. PubMed ID: 25603726
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Use of PEG-asparaginase in newly diagnosed adults with standard-risk acute lymphoblastic leukemia compared with E. coli-asparaginase: a retrospective single-center study.
    Liu WJ; Wang H; Wang WD; Zhu MY; Liu CC; Wang JH; Lu Y
    Sci Rep; 2016 Dec; 6():39463. PubMed ID: 28000713
    [TBL] [Abstract][Full Text] [Related]  

  • 49. L-asparaginase induced intracranial haemorrhage in acute lymphoblastic leukemia.
    Lim HL; Teo CP; Wong K; Kueh YK
    Singapore Med J; 1998 Feb; 39(2):76-8. PubMed ID: 9652181
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Asparaginase in acute lymphoblastic leukemia.
    Kawedia JD; Rytting ME
    Clin Lymphoma Myeloma Leuk; 2014 Sep; 14 Suppl():S14-7. PubMed ID: 25486949
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Prophylaxis of thromboembolism during therapy with asparaginase in adults with acute lymphoblastic leukaemia.
    Rank CU; Lynggaard LS; Als-Nielsen B; Stock W; Toft N; Nielsen OJ; Frandsen TL; Tuckuviene R; Schmiegelow K
    Cochrane Database Syst Rev; 2020 Oct; 10(10):CD013399. PubMed ID: 33038027
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Evaluation for inherited and acquired prothrombotic defects predisposing to symptomatic thromboembolism in children with acute lymphoblastic leukemia: a protocol for a prospective, observational, cohort study.
    Athale UH; Laverdiere C; Nayiager T; Delva YL; Foster G; Thabane L; Chan AK
    BMC Cancer; 2017 May; 17(1):313. PubMed ID: 28472942
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Reducing venous thrombosis with antithrombin supplementation in patients undergoing treatment for ALL with Peg-asparaginase-A real world study.
    George G; Rezazadeh A; Zook F; Pearl N; McCoy C; Carlson K; Runaas L; Abedin S; Guru Murthy GS; Michaelis LC; Atallah E; Baumann-Kreuziger L
    Leuk Res; 2020 Jul; 94():106368. PubMed ID: 32442786
    [No Abstract]   [Full Text] [Related]  

  • 54. Treatment-induced cerebral sinus venous thrombosis in childhood acute lymphoblastic malignancies: New risk factors to consider.
    El-Khoury H; Saifi O; Haddad S; Chahrour M; Ghanem KM; Mubarak Y; Tamim H; Makki M; Zakka C; Chan AK; Mahfouz R; Tarek N; El-Solh H; Abboud MR; Saab R; Muwakkit SA
    Pediatr Blood Cancer; 2021 Nov; 68(11):e29210. PubMed ID: 34327817
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Outcome of adults with acute lymphoblastic leukemia treated with a pediatric-inspired therapy: a single institution experience.
    Ruiz-Delgado GJ; Macías-Gallardo J; Lutz-Presno JA; Montes-Montiel M; Ruiz-Argüelles GJ
    Leuk Lymphoma; 2011 Feb; 52(2):314-6. PubMed ID: 21054153
    [No Abstract]   [Full Text] [Related]  

  • 56. Toxicity profile of repeated doses of PEG-asparaginase incorporated into a pediatric-type regimen for adult acute lymphoblastic leukemia.
    Aldoss I; Douer D; Behrendt CE; Chaudhary P; Mohrbacher A; Vrona J; Pullarkat V
    Eur J Haematol; 2016 Apr; 96(4):375-80. PubMed ID: 26095294
    [TBL] [Abstract][Full Text] [Related]  

  • 57. [The feasibility of Erwinia asparaginase for pediatric patients who developed an allergic reaction to E.coli asparaginase during treatment of acute lymphoblastic leukemia].
    Takahashi H; Koh K; Kato M; Isobe K; Yasui N; Mori M; Akiyama K; Kikuchi A; Hanada R
    Rinsho Ketsueki; 2013 Apr; 54(4):370-7. PubMed ID: 23666219
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Weekly polyethylene glycol conjugated L-asparaginase compared with biweekly dosing produces superior induction remission rates in childhood relapsed acute lymphoblastic leukemia: a Pediatric Oncology Group Study.
    Abshire TC; Pollock BH; Billett AL; Bradley P; Buchanan GR
    Blood; 2000 Sep; 96(5):1709-15. PubMed ID: 10961868
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Asparaginase-Associated Pancreatitis in Acute Lymphoblastic Leukemia: Results From the NOPHO ALL2008 Treatment of Patients 1-45 Years of Age.
    Rank CU; Wolthers BO; Grell K; Albertsen BK; Frandsen TL; Overgaard UM; Toft N; Nielsen OJ; Wehner PS; Harila-Saari A; Heyman MM; Malmros J; Abrahamsson J; Norén-Nyström U; Tomaszewska-Toporska B; Lund B; Jarvis KB; Quist-Paulsen P; Vaitkevičienė GE; Griškevičius L; Taskinen M; Wartiovaara-Kautto U; Lepik K; Punab M; Jónsson ÓG; Schmiegelow K
    J Clin Oncol; 2020 Jan; 38(2):145-154. PubMed ID: 31770057
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Improved Outcome of a Pediatric-Inspired Protocol for High-Risk Adolescent and Young Adult Acute Lymphoblastic Leukemia Patients Using Peg-Asparaginase and Escalating Dose of Methotrexate: Tolerability and Outcome.
    Hanbali A; Kotb A; El Fakih R; Alfraih F; Ahmed SO; Shaheen M; Hashmi S; Alhayli S; Alahmari A; Riash MA; Rasheed W; Alzahrani H; Alsharif F; Chaudhri N; Almohareb F; Aljurf M
    Clin Lymphoma Myeloma Leuk; 2019 Oct; 19(10):670-677. PubMed ID: 31377206
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.